Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Transplantation and cellular therapy·2026
Same author

Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma.

Transplantation and cellular therapy·2026
Same author

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT.

Blood·2025
Same author

Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.

Blood advances·2025
Same author

Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.

Blood advances·2025
Same author

Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.

Leukemia·2025

Related Experiment Video

Updated: Apr 27, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K

It is time to move forward with Waldenström!

Yvonne A Efebera1

  • 1OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER.

Blood
|June 28, 2014
PubMed
Summary

High expression of C-X-C chemokine receptor type 4 (CXCR4) mutations in Waldenström macroglobulinemia (WM) drives tumor aggression and resistance. Targeting CXCR4 with an antibody reversed these effects in preclinical models, offering new therapeutic avenues for WM.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Waldenström macroglobulinemia (WM) is a rare B-cell lymphoproliferative disorder.
  • Tumor aggression and drug resistance remain significant challenges in WM management.
  • The role of specific molecular markers in WM pathogenesis is an area of active investigation.

Purpose of the Study:

  • To investigate the expression and functional significance of C-X-C chemokine receptor type 4 (CXCR4) mutations in Waldenström macroglobulinemia (WM).
  • To evaluate the therapeutic potential of targeting CXCR4 in preclinical WM models.

Main Methods:

  • Analysis of CXCR4 expression and mutation status in WM patient samples.
  • In vivo studies using xenograft models of WM.
  • Treatment of WM models with an anti-CXCR4 antibody.

More Related Videos

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

15.5K
Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

30.2K

Related Experiment Videos

Last Updated: Apr 27, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

15.5K
Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

30.2K

Main Results:

  • High expression of CXCR4 mutations was observed in WM, correlating with tumor aggression.
  • In vivo administration of an anti-CXCR4 antibody effectively reversed tumor aggression.
  • Targeting CXCR4 demonstrated a significant impact on disease progression in preclinical settings.

Conclusions:

  • CXCR4 mutation is a key driver of tumor aggression and drug resistance in WM.
  • Anti-CXCR4 antibody therapy shows promise as a novel treatment strategy for WM.
  • Further clinical investigation of CXCR4-targeted therapies in WM is warranted.